安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Pfizer: One of the worlds premier biopharmaceutical companies
Pfizer RxPathways Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings
- Pfizer: One of the worlds premier biopharmaceutical companies
Diverse perspectives help solve impossible problems Representation in healthcare is not just important — it’s vital Our core values are simple and interconnected: courage, e
- Pfizer’s Core Values of Social Responsibility and Philanthropy
The Best Get Better—Pfizer and Warner-Lambert merge to form the new Pfizer, creating the world's fastest-growing major pharmaceutical company Learn more about the Pfizer Warner-Lambert merger
- Newsroom - Pfizer
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind
- Our Products: Holding the Promise of a Breakthrough | Pfizer
In this section find an overview of our Pfizer Products and search for information on our most popular Pfizer products Our products are the results of 1500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription
- Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to . . .
This release contains forward-looking information abouttilrekimig (PF-07275315), an investigational trispecific antibody, including its potential benefits; results from the Phase 2 study of tilrekimig in participants with moderate to severe atopic dermatitis; Pfizer’s investigational inflammation and immunology portfolio, and anticipated
- Our Science: Pharmaceutical Development - Pfizer
At Pfizer our biotechnology is our foundation With 25,000 clinical researchers testing everyday, pharmaceutical development and innovation are our focus Learn more
- Pfizer Inc. - Investor Relations
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer Read More View All News Latest Quarter | Q4 2025
|
|
|